PROJECT STAGE
Lead optimisation
Hit to lead
Screening
Assay Development
Therapeutic area
  • Alzheimer’s Disease

Project Aim

To develop a humanised antibody that specifically targets toxic species of Aβ for Alzheimer’s Disease

Advantage

A novel approach to specifically target Aβ N-terminal oligomers

Target Class

Extracellular Protein

Modality

Antibody

Current Status

Lead with in-vivo proof of concept

Intellectual Property

Existing patent applications with scope for additional IP protection

Offering

Licence or collaboration for preclinical / clinical development

Key Contact

  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email support@thewebkitchen.co.uk.
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
  • We would love to send you information about LifeArc news and events. Please let us know if you would like us to contact you by selecting one of the following options:
All Licensing Opportunities